Overcome Sterility Testing Challenges for Complex Drug Product Formulations
Complex drug products and advanced drug delivery systems allow unprecedented therapeutic control and efficacy but strain traditional microbial quality checks. This overview covers pharmaceutical formulations posing particular sterility testing challenges.
-
Advanced Drug Delivery Systems (ADDS)
Advanced Drug Delivery Systems (ADDS) are designed to release drugs in a controlled manner, optimizing therapeutic effects while minimizing side effects. These systems are particularly important in the development of sustained release or long-acting injectable products, which are not simple aqueous formulations. These include: Long-Acting Injectables/Depot Delivery Systems, Mechanical Force-Triggered Drug Delivery, Injectable In-Situ Forming Implants (ISFIs), and Polymer Nanoparticle and microparticle Carriers.
-
Cell Therapies and Biologics
These complex drug products often exhibit high viscosity or turbidity due to the presence of therapeutic cells and components in high titers. The presence of living cells in these therapies can complicate the detection of microbial contamination, as they can mask or interfere with the identification of harmful microorganisms. Traditional sterility testing methods are less effective due to these inherent characteristics.
-
Products with Adjuvants and Preservatives
These pharmaceutical formulations contain substances that enhance the product's effect (adjuvants) or extend shelf life (preservatives). These additives can interfere with microbial growth through inhibition, delay, or stressing microbial growth in sterility testing, potentially leading to false-negative results. This makes it challenging to accurately assess the sterility of these products.
-
Nanosuspensions, Microsphere Suspensions and Oil-Emulsions
These formulations, particularly those containing nanoparticles, present challenges in filtration due to their unique physical properties. Nanoemulsions are known for their ability to enhance the solubility and bioavailability of poorly soluble drugs. Oil-in-water emulsions, composed of oil droplets dispersed in an aqueous phase, provide unique solutions for overcoming drug delivery challenges, especially for drugs that are poorly soluble in water. They may not be suitable for direct inoculation methods used in traditional sterility testing, necessitating alternative approaches.
-
Highly Viscous or Lipid-based Products
Complex drug products with high viscosity or significant lipid content can pose challenges in filtration processes. Such products often require specialized techniques or adaptations of standard sterility testing methods to ensure accurate results.
By evolving sterile testing to match sophisticated drug platforms, manufacturers can accelerate patient access for pioneering medicines while optimizing operations, supply chain fluidity, and patient safety guardrails.
Dealing with Innovative Formulations that Cloud Sterility Testing?
Learn how updated sterility testing methods and drug delivery technologies address the unique challenges posed by modern pharmaceuticals, particularly those with complex compositions or inherent turbidity.
Discover the approach
The Impact of Rapid Microbiological Methods for Complex Parenteral Products
For challenging and inherently turbid products, reducing the testing time from potentially 21 days to 7 days can be significant, eliminating the need for sub-culturing and reducing contamination risks. The elimination of the sub-culture step can also provide additional capacity for sterility testing isolators.
Celsis provides new ways to optimize the test method, such as transitioning from direct inoculation to a hybrid-membrane filtration, improving your standard test method and meeting recommendations by pharmacopeia for Membrane Filtration over Direct Inoculation whenever its feasible. The adoption of membrane filtration provides additional robustness in routine sterility testing, by reducing the opportunity for products to interfere with microbial proliferation during the incubation period.
Celsis ATP-bioluminescence provides a rapid, robust, and reliable sterility test for inherently turbid pharmaceutical products, not relying on subjective turbidity measurements.
Get Fast, Robust Results →
- Reduces overall time and provides definitive results by eliminating the need for extensive follow-up testing and investigations to rule out contamination
- Lowers regulatory risk that comes with repeat test investigations, which draw further scrutiny and examination around potential false positives
Start saving now →
- Delivers quantifiable cost savings in the areas of personnel, consumable, inventory, and production
- The hard cost savings make a tangible business case beyond typical reduced quarantine duration, organizations expect a 14-day test and plan accordingly
Uplift Your Sterility Testing
The Celsis ATP-bioluminescence system delivers speed, reliability, and cost efficiency along with regulatory risk reduction for organizations struggling with sterility testing ambiguities caused by turbid product matrices. By modernizing this quality process, it provides definitive contamination assessment and accelerated batch dispositions.
Explore the Celsis® Rapid Microbial Detection Brochure
Gain insight into Celsis® technologies, platform capabilities, implementation considerations, validation support, and microbial detection applications across a range of product types.
Access the Brochure